StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

Research analysts at StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $4.25 price objective on shares of OncoCyte in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.06.

OncoCyte Stock Up 11.3 %

OCX opened at $3.34 on Friday. The firm’s fifty day moving average price is $3.13 and its two-hundred day moving average price is $2.93. OncoCyte has a 1 year low of $2.08 and a 1 year high of $4.34.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. The company had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.